XML 147 R23.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Product Revenue
 12 Months Ended
Dec. 31, 2019
Revenue from Contract with Customer [Abstract]  
Product Revenue Product Revenue
The Company’s product sales are derived from the sale of ABRAXANE, REVLIMID, and VIDAZA in China under a distribution license from BMS. Following FDA approval on November 14, 2019, the Company launched its first internally developed drug, BRUKINSA, and began generating product revenues in the United States.
The table below presents the Company’s net product sales for the years ended December 31, 2019, 2018 and 2017.
 
Year Ended
December 31,
 
2019
 
2018
 
2017
 
$
 
$
 
$
Product revenue - gross
228,760

 
138,046

 
28,428

Less: Rebates and sales returns
(6,164
)
 
(7,161
)
 
(4,000
)
Product revenue - net
222,596

 
130,885

 
24,428


The following table presents the rollforward of accrued sales rebates and returns for the years ended December 31, 2019 and December 31, 2018.
 
Sales Rebates and Returns
 
$
Balance as of December 31, 2017
3,997

Accrual
7,161

Payment
(6,409
)
Balance as of December 31, 2018
4,749

Accrual
6,164

Payment
(7,715
)
Balance as of December 31, 2019
3,198